The phase III study FIND-CKD—investigating the efficacy and safety of Kerendia (finerenone, Bayer) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD)—has met its primary endpoint.
The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from baseline to month 32, a validated surrogate endpoint for kidney disease progression. The safety profile of Kerendia in the FIND-CKD study was consistent with its established safety profile.
The FIND-CKD clinical trial data will be presented at an upcoming scientific conference. Bayer anticipates submitting the data to the US Food and Drug Administration (FDA) to extend the indication of KERENDIA to non-diabetic CKD patients.
“Patients with chronic kidney disease have substantial risk for cardiovascular events and kidney failure, so new treatments are needed to help slow kidney disease progression and improve outcomes,” said Hiddo L Heerspink (University Medical Center Groningen, Groningen, the Netherlands), co-chair of the study’s executive committee. “The FIND-CKD topline results are encouraging because they now provide evidence for finerenone in a non-diabetic chronic kidney disease population, on top of its established evidence in diabetic chronic kidney disease.”
Since 2021, Kerendia has been approved to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), non-fatal myocardial infarction, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with type 2 diabetes (T2D). In July 2025, KERENDIA also received FDA approval for the treatment of heart failure with left ventricular ejection fraction (HF LVEF) ≥40%.
“The FIND‑CKD findings mark the fifth consecutive phase III trial in the Kerendia clinical development program to meet its primary endpoint and represent a major milestone for people living with non-diabetic chronic kidney disease,” said Carolina Aldworth, executive medical director at Bayer. “When considered alongside the growing evidence base, this important trial adds to our understanding of Kerendia across multiple patient populations with heart and kidney diseases.”
Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) that selectively and potently blocks mineralocorticoid receptor overactivation in the heart and kidneys. FIND-CKD is the largest phase III study to date focused on non-diabetic CKD and investigated KERENDIA in a population spanning different aetiologies of non-diabetic CKD.
